ReNeuron raises funds as it awaits review from first treatment of stem cell therapy
This article was originally published in Scrip
Executive Summary
ReNeuron has raised £10 million by means of a share placing and subscription with new and existing investors on London's AIM. The stem cell-focused company says the financing provides preclinical and clinical development funding for core therapeutic programmes for the next two years, after which it believes that out-licensing deals will be possible for these programmes.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.